These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30333046)

  • 1. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
    Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
    Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
    World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R
    Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
    BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
    Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
    Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.
    Kumari K; Dandapath I; Singh J; Rai HIS; Kaur K; Jha P; Malik N; Chosdol K; Mallick S; Garg A; Suri A; Sharma MC; Sarkar C; Suri V
    Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):410-417. PubMed ID: 35708480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
    Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
    Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
    Terzi NK; Yilmaz I; Oz AB
    Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
    Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
    [No Abstract]   [Full Text] [Related]  

  • 15. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
    Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP
    Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
    Qiu X; Chen Y; Bao Z; Chen L; Jiang T
    Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
    Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
    J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.
    Ishi Y; Yamaguchi S; Okamoto M; Sawaya R; Endo S; Motegi H; Terasaka S; Tanei ZI; Hatanaka KC; Tanaka S; Fujimura M
    Brain Tumor Pathol; 2022 Jul; 39(3):162-170. PubMed ID: 35362874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report.
    Wang H; Tan C; Xu T; Li W
    Folia Neuropathol; 2021; 59(1):104-111. PubMed ID: 33969682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
    Muench A; Teichmann D; Spille D; Kuzman P; Perez E; May SA; Mueller WC; Kombos T; Nazari-Dehkordi S; Onken J; Vajkoczy P; Ntoulias G; Bettencourt C; von Deimling A; Paulus W; Heppner FL; Koch A; Capper D; Kaul D; Thomas C; Schweizer L
    Am J Surg Pathol; 2023 Dec; 47(12):1364-1375. PubMed ID: 37737691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.